Olema Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Olema Pharmaceuticals Inc (OLMA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 67.7% of the shares are freely tradable; institutional investors hold 119.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.88 | 12,143,062 | +16.9 | 06/30/2026 |
| Paradigm Biocapital Advisors LP | 9.91 | 8,670,576 | +8.1 | 06/30/2026 |
| HHG PLC | 8.12 | 7,108,488 | +5.9 | 03/31/2026 |
| Jupiter Topco LLC | 8.11 | 7,094,413 | +0.0 | 06/30/2026 |
| Bain Capital Life Sciences Investors, LLC | 8.10 | 7,085,249 | -5.2 | 06/30/2026 |
| BlackRock Inc | 7.67 | 6,714,691 | +18.8 | 06/30/2026 |
| Bvf Inc | 6.05 | 5,295,893 | +0.0 | 06/30/2026 |
| Siren, L.L.C. | 5.55 | 4,856,949 | +2.1 | 06/30/2026 |
| State Street Corp | 4.93 | 4,316,058 | +9.6 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.82 | 3,341,217 | +8.4 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Harmon Cyrus | Director | 702,770 | 5,200,498 $ | Jul 24, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | Harmon Cyrus | Director | Sell | 12,500 | 11.71 | 146,425 |
| Jul 23, 2026 | Harmon Cyrus | Director | Sell | 12,500 | 11.58 | 144,738 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.